Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Angela Smiley, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Andrew W. Roberts, MBBS, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Richard De Abreu Lourenco, Andrew Spencer, MD

Blood (2013) 122 (21): 537.

https://doi.org/10.1182/blood.V122.21.537.537

Published: 2013

Journal Articles

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit S Khot, MBBS, MD, MRCP (UK), FRCPath, Tsin Tsin, Andy Hsu, PhD, Karen Chen, Maureen Loudovaris, Paul Neeson, PhD, Dominic Wall, PhD, Rebecca Sedunary, H. Miles Prince, MBBS, FRACP, FRCPA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD

Blood (2011) 118 (21): 1862.

https://doi.org/10.1182/blood.V118.21.1862.1862

Published: 2011

Journal Articles

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, Swaminathan Padmanabhan, MBBS, MD, Andrei R. Shustov, MD, Jean Nichols, PhD, Susan Carroll, John Balser, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 591.

https://doi.org/10.1182/blood.V118.21.591.591

Published: 2011

Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD

Blood (2010) 116 (21): 1961.

https://doi.org/10.1182/blood.V116.21.1961.1961

Published: 2010

Journal Articles

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Michael J. Dickinson, MBBS, Rosemary Hoyt, BN, Andrew Roberts, MBBS PhD, Andrew Grigg, MBBS, John Francis Seymour, MBBS PhD, Jeff Szer, MBBS BSc BMedSci, H. Miles Prince, MBBS(Hons)MD, David Ritchie, MBChB PhD

Blood (2007) 110 (11): 5115.

https://doi.org/10.1182/blood.V110.11.5115.5115

Published: 2007

Journal Articles

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

John Francis Seymour, MBBS, FRACP, Ashley Ng, MBBS, BMedSci, Leon Worth, MBBS, Monica Slavin, MBBS, FRACP, H. Miles Prince, MBBS, FRACP, Karin Thursky, MBBS, FRACP

Blood (2004) 104 (11): 3837.

https://doi.org/10.1182/blood.V104.11.3837.3837

Published: 2004

Journal Articles

Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.

Anthony K. Mills, MBBS, Simon Gibbs, MBBS, Colm Keane, MBBCh BAO, Peter Mollee, MBBS, Karen Grimmett, BApSc, Rosita Van Kuilenburg, Russell Saal, BApSc MMedSci, Devinder Gill, MBChB, H. Miles Prince, MBBS, John F. Seymour, MBBS, Paula Marlton, MBBS

Blood (2004) 104 (11): 5213.

https://doi.org/10.1182/blood.V104.11.5213.5213

Published: 2004

Journal Articles

A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.

Paul J. Shaughnessy, MD, Brian J. Bolwell, MD, Sunil Abhyankar, MD, Koen van Besien, MD, Martin Mistrik, MD PhD, Andrew Grigg, MBBS, Anthony Dodds, MBBS, H. Miles Prince, MBBS, Alexandra Machado, MD, Ulrich Thienel, MD, PhD, Jim Wang, Francine Foss, MD, Jane Apperley, MBChB

Blood (2004) 104 (11): 1230.

https://doi.org/10.1182/blood.V104.11.1230.1230

Published: 2004

NARROW

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.

A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only